Erica Evans, Ph.D., is MOMA’s vice president of biology and translational sciences. She joined the company in 2020, built the biology team, and is responsible for overseeing MOMA’s biology activities including target validation and selection, drug discovery program support and translational studies.
Prior to MOMA, Erica spent over seven years at Blueprint Medicines. There she led two drug discovery programs, one targeting KIT D816V and the other targeting RET activating fusions and mutations, both from early drug discovery through phase 1 clinical proof of concept and remained involved through NDA filing. Both programs resulted in FDA approved drugs (AYVAKIT and GAVRETO). Before Blueprint Medicines, Erica worked on covalent small molecule inhibition for over 5 years at Avila Therapeutics beginning in Avila’s early stages through its acquisition by Celgene.
Erica received her Ph.D. from the Department of Pharmacology and Molecular Cancer Biology at Duke University where she studied in Dr. Sally Kornbluth’s laboratory and received her bachelor’s degree in biology from Harvard University.